Neumora Therapeutics upgraded to Outperform by RBC Capital Markets

RBC Capital Markets upgraded Neumora Therapeutics from Sector Perform to Outperform, increasing its price forecast from $4 to $7. The company is expanding its obesity and metabolic pipeline, with a competitive early asset demonstrating emerging promise across multiple large-market indications. Analyst Brian Abrahams expects data in 2026 to better define the target's potential and have meaningful positive readthroughs to Neumora.